Clonality Analysis in Modern Oncology and Surgical Pathology

Liang Cheng, MD, Shaobo Zhang, MD, Timothy D. Jones, MD, and Deborah E. Blue, MD

CONTENTS

I. Clonal Expansion is the Hallmark of Neoplasia
   Overview ..................................................11-3
   Tumorigenesis Models ..................................11-3
     Monoclonal Tumor Model ............................11-3
     Multi-Step Carcinogenesis ..........................11-4
   Polyclonal Tumor Model .............................11-5
   Patch Phenomenon ....................................11-6

II. X Chromosome-Linked Clonality Analysis
    Principle and Implication of X Chromosome Inactivation ..................11-7
    X Chromosome Inactivation
      Control Mechanisms ..............................11-9
    Human Androgen-Receptor Gene
      X Chromosome Inactivation Analysis ............11-9
      Advantages and Limitations ....................11-12
      Technical Considerations ......................11-12
    Other X Chromosome-Linked Clonality Analyses ...........................................11-15
    Selected Applications ............................11-16

III. Loss of Heterozygosity (LOH) as a Clonal Marker
     Overview ...............................................11-17
     Evaluation and Interpretation .....................11-18
     Advantages and Limitations .....................11-19
     Technical Considerations ......................11-19

     Allele Drop-Off ..................................11-19
     Loss of Sensitivity ..............................11-19
     LOH in Normal Cells ..............................11-19
     Methods of LOH Analysis .......................11-19
       Radioisotope PCR Incorporation-Gel
        Electrophoresis ................................11-19
       High-Resolution Fluorescent
         Chromatography (HPLC) ........................11-20
         High-Performance Liquid
           Chromatography (HPLC) .......................11-20

IV. Other Methods of Clonality Analysis
    Advantages and Limitations .....................11-21
    Technical Considerations ......................11-21
    Methods of LOH Analysis .......................11-22
      Radioisotope PCR Incorporation-Gel
        Electrophoresis ................................11-22
      High-Resolution Fluorescent
        Chromatography (HPLC) .......................11-22
      High-Performance Liquid
        Chromatography (HPLC) .......................11-22
    Selected Applications ............................11-22

     Somatic Mutation ..............................11-21
     Gene Rearrangement Analysis ....................11-23
     Cyto genetic Analysis and FISH ..................11-23
     DNA Methylation as a Clonal Marker ..........11-25
     Microsatellite Instability ......................11-25
     Viral Integration Analysis ......................11-27
     Comparative Genomic
       Hybridization (CGH) ..........................11-27
     Gene Expression Profiling/Array-Based
       Clonality Analysis ............................11-28
     MicroRNA Signatures ............................11-28
     Protein-Based Clonality Analysis ............11-28
V. Tissue Contamination and Patient Identity Mismatch Testing ....11-29
   Overview ........................................11-29
   Technical Approaches ..........................11-29
   Caveats ...........................................11-31

VI. Identification of Donor Origin in Transplantation Patients ....11-32
   Overview ........................................11-32
   Technical Approaches ..........................11-33
   Caveats ...........................................11-33

VII. Bone Marrow Engraftment Testing ..........................11-34
   Overview ........................................11-34
   Technical Approaches ..........................11-34
   Caveats ...........................................11-35

VIII. Molecular Diagnosis of Hydatidiform Mole .................11-35
   Overview ........................................11-35
   Technical Approaches ..........................11-35
   Caveats ...........................................11-36

IX. Cancer of Unknown Primary Origin (CUP) .....................11-36
   Overview ........................................11-36
   Technical Approaches ..........................11-37
     Clinical .......................................11-37
     Pathology ......................................11-37
     Molecular ......................................11-38

X. Summary ........................................11-39

XI. Suggested Reading ................................11-39